OCUGEN, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On January 8, 2022, Ocugen, Inc. issued a press release announcing that its partner, Bharat Biotech International Limited, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™ (BBV152), in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. A copy of this press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits.

The following exhibits are being filed herewith:

(d) Exhibits



Exhibit No.   Document

  99.1          Press Release of Ocugen, Inc. dated January 8, 2022.
              Cover Page Interactive Data File (embedded within the Inline XBRL
104           document).




                                       1

© Edgar Online, source Glimpses